Condition: Obesity and Type 2 Diabetes · Sponsor: Korea University Anam Hospital
The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.
This description comes directly from the study's public registry record.
So Ree Kim, MD, PhD · 82029205445 · soree8826kim@gmail.com
Seong-Mi Park, M.D., Ph.D. · 82029205445 · smparkmd@korea.ac.kr
Always discuss trial participation with your own doctor first.
| Korea University Anam Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06782139